

Real-World HIV Patient Experience with Long-Acting Ibalizumab

Brian Beesley, DO¹, Pedro Mesquita, PhD², Christophe Guilé, PharmD², Joan Day, MS³
¹Columbus, Ohio; ²Theratechnologies Inc., Montreal, QC, Canada; ³Day & Associates, San Mateo, California



Introduction

IBALIZUMAB

- Ibalizumab (IBA) was approved in 2018 as the first long-acting monoclonal antibody for HIV
- IBA is a CD4-directed post-attachment HIV-1 inhibitor that is indicated, in combination with other antiretroviral(s), for the treatment of HIV infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen
- TROGARZO[®] is administered intravenously (IV) as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every 2 weeks
- Adherence-related factors play a significant role in virologic failure in the heavily-treatment experienced HIV population

OBJECTIVE

- Since patient satisfaction with antiretroviral therapy (ART) may impact adherence and clinical outcomes, we sought to assess real-world patient experience with IBA and acceptance of IV administration

METHODS

- 30 IBA patients completed a brief online questionnaire regarding their experience with IBA
- This questionnaire was conducted by an independent market research firm on behalf of Theratechnologies
- Outreach included only patients who had opted-in to being contacted
- 20 questions of varying types were used in the questionnaire, including:
 - Likert scales
 - Dichotomous questions
 - Checklist-type multiple choice
 - Open-ended questions
- Results were analyzed in aggregate and by infusion setting (i.e. health care provider [HCP] clinic, infusion center, or at home)
- The survey was single-blind, meaning that no personal identifiable information was shared with Theratechnologies
- All surveys were completed between December 2020 and March 2021
- All participants were compensated for their time

Results


PARTICIPANT CHARACTERISTICS

- Of the 30 respondents to the questionnaire:
 - 83% were male; 17% were female
 - Overall average age of 55 years
 - Average time on IBA treatment was 8.5 months
 - Duration of treatment ranged from 1 to 18 months
 - Data was available for 15 respondents only
- All respondents were currently on therapy therefore clinical outcome may have influenced the results which could vary among other patients treated with IBA


PATIENT SATISFACTION

A. Experience

- 87% of patients who responded to the questionnaire were “very satisfied” with their IBA experience, primarily due to efficacy and results of treatment
- None of the respondents expressed dissatisfaction with IBA



- The majority of respondents indicated their experience with IBA was better than they expected



- On an unaided basis, 77% of respondents described efficacy (e.g. viral load) or quality of life as a benefit of IBA, however, clinical outcome data were not collected


Results (cont'd)

PATIENT SATISFACTION (CONT'D)

B. Experience by Infusion Setting


- Although patient experience was very positive regardless of infusion setting, higher ratings were reported among patients receiving IBA in the clinic vs. at home

Level of Agreement with Statements by IBA Infusion Setting*




C. Convenience

- We found high acceptability of the IV administration, with 93% rating the infusion process as “very convenient” or “neutral”



- Patients felt that administration of IBA was not complicated
 - Patients expressed strong disagreement with the statement “the IV administration of IBA has been difficult for me”




Results (cont'd)

PATIENT ADHERENCE

A. Experience with HCP Touchpoints Every Two Weeks

- There is very high satisfaction with the experience getting the infusion and seeing an HCP every 2 weeks
- Of 4 respondents rating their experience as somewhat less positive, 3 are receiving the treatment at home


Respondent Rating of Experience Seeing Their HCP for IBA Infusion Every 2 Weeks*



B. Impact of Touchpoints Every Two Weeks

- According to 80% of respondents, having a 2-week touchpoint with their HCP is likely to support adherence to other HIV medications

Ability to Help Patients Be More Adherent to Other HIV Medications




Results (cont'd)

PATIENT ADVOCACY

- Treatment satisfaction was further underscored by strong patient advocacy, with 93% likely to recommend IBA to another patient
- All but 2 patients would recommend TROGARZO[®] to another patient, mostly based on efficacy and ease of use


Likelihood to Recommend IBA to Another Patient



PATIENT SUPPORT

- Patients also expressed very high satisfaction with the THERA Patient Support Program, which provides services including enrollment assistance, reimbursement navigation and financial assistance, as well as infusion coordination and supports

Satisfaction with THERA Patient Support*



Conclusions

- This study highlights favorable experience and satisfaction with IBA, resulting in strong patient advocacy.
- Importantly, frequent HCP contact was perceived as helpful to improve ART adherence, supporting IBA as a valuable option for treatment experienced HIV patients
- High acceptance of IV therapy warrants the inclusion of this long-acting treatment in discussions with patients failing their current regimen